SAN FRANCISCO--(BUSINESS WIRE)--Medivation, Inc. (AMEX:MDV) today announced that on September 27, 2006 it received permission from the FDA to begin the Company’s U.S. Phase 1-2a clinical trial of Dimebon™ in patients with Huntington’s disease. Medivation expects patient dosing to begin in early October.
